Morgan Stanley’s Addex Therapeutics ADXN Stock Holding History

Morgan Stanley’s Portfolio ADXN Stock Details ADXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-301	Closed	-$1.89K	–	8407
2026 Q1	$1.89K	Buy	301 +1	+0.3%	+$7	﹤0.01%	7341
2025 Q4	$2.32K	Buy	+300	New	+$2.57K	﹤0.01%	7217
2025 Q3	–	Sell	-100	Closed	-$941	–	8162
2025 Q2	$941	Hold	100	–	–	﹤0.01%	7340
2025 Q1	$734	Sell	100 -1,800	-95%	-$13.9K	﹤0.01%	7324
2024 Q4	$13.3K	Buy	1,900 +1,547	+438%	+$14.1K	﹤0.01%	6703
2024 Q3	$3.45K	Sell	353 -1,147	-76%	-$10.2K	﹤0.01%	7007
2024 Q2	$12.3K	Buy	+1,500	New	+$18.5K	﹤0.01%	6609

Other funds holding ADXN

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Morgan Stanley's ADXN Position: Q2 2026 in Review

Morgan Stanley sold out of Addex Therapeutics (ADXN) in Q2 2026, closing a stake of 301 shares — an estimated $1.89K sold.

Morgan Stanley first reported a position in ADXN in Q2 2024 and held it in 7 quarters. The position peaked at $13.3K in Q4 2024. 2 funds tracked by Wall St. Rank hold ADXN as of Q2 2026.

Morgan Stanley reported no remaining Addex Therapeutics position as of Q2 2026 after selling out during the quarter.
Morgan Stanley sold 301 Addex Therapeutics shares in Q2 2026, an estimated $1.89K.
Morgan Stanley first reported a position in Addex Therapeutics in Q2 2024 and held it in 7 quarters.
Morgan Stanley's Addex Therapeutics position peaked at $13.3K in Q4 2024.
2 funds tracked by Wall St. Rank held Addex Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.